Acute pancreatitis resident survival guide: Difference between revisions

Jump to navigation Jump to search
 
(15 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}} {{AE}} {{VB}} {{VR}}
{{CMG}}; {{AE}} {{VB}}; {{VR}}


==Definition==
==Overview==
Acute pancreatitis is an acute inflammation of the [[pancreas]].
Acute pancreatitis is the acute inflammation of the [[pancreas]].


==Diagnostic Criteria==
==Diagnostic Criteria==
▸ Diagnosis is established by the presence of two of the three following criteria ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]):<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
▸ Diagnosis is established by the presence of two of the three following criteria ([[GRADE system classification scheme|strong recommendation, moderate quality of evidence]]):<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back).'''
* '''Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back)'''
<!--
<!--
::* A dull, colicky pain located in the lower abdomen suggests an alternative etiology.
::* A dull, colicky pain located in the lower abdomen suggests an alternative etiology.
-->
-->
* '''Serum [[lipase]] or [[amylase]] ≥ 3 x ULN.'''
* '''Serum [[lipase]] or [[amylase]] ≥ 3 x ULN'''
<!--
<!--
::* Amylase may be falsely elevated in [[appendicitis]], [[cholecystitis]], [[intestinal obstruction]] or [[Mesenteric ischemia|ischemia]], [[perforated ulcer]], [[salivary gland]] disease, gynecological disease, renal disease, and [[macroamylasemia]].
::* Amylase may be falsely elevated in [[appendicitis]], [[cholecystitis]], [[intestinal obstruction]] or [[Mesenteric ischemia|ischemia]], [[perforated ulcer]], [[salivary gland]] disease, gynecological disease, renal disease, and [[macroamylasemia]].
Line 17: Line 17:
::* Lipase may be falsely elevated in [[appendicitis]], [[cholecystitis]], renal disease, and macrolipasemia.
::* Lipase may be falsely elevated in [[appendicitis]], [[cholecystitis]], renal disease, and macrolipasemia.
-->
-->
* '''Characteristic findings on contrast-enhanced [[computed tomography|CT]], [[magnetic resonance imaging|MRI]], or transabdominal [[ultrasonography|US]].'''
* '''Characteristic findings on contrast-enhanced computed tomography (CECT), [[magnetic resonance imaging|MRI]], or transabdominal [[ultrasonography|US]]'''
<!--
<!--
::* If abdominal pain strongly suggests acute pancreatitis but pancreatic enzyme is less than three times the upper limit of normal, a confirmatory imaging is required.<ref name="Bollen-2007">{{Cite journal  | last1 = Bollen | first1 = TL. | last2 = van Santvoort | first2 = HC. | last3 = Besselink | first3 = MG. | last4 = van Es | first4 = WH. | last5 = Gooszen | first5 = HG. | last6 = van Leeuwen | first6 = MS. | title = Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. | journal = Semin Ultrasound CT MR | volume = 28 | issue = 5 | pages = 371-83 | month = Oct | year = 2007 | doi =  | PMID = 17970553 }}</ref><ref name="Morgan-2008">{{Cite journal  | last1 = Morgan | first1 = DE. | title = Imaging of acute pancreatitis and its complications. | journal = Clin Gastroenterol Hepatol | volume = 6 | issue = 10 | pages = 1077-85 | month = Oct | year = 2008 | doi = 10.1016/j.cgh.2008.07.012 | PMID = 18928934 }}</ref>
::* If abdominal pain strongly suggests acute pancreatitis but pancreatic enzyme is less than three times the upper limit of normal, a confirmatory imaging is required.<ref name="Bollen-2007">{{Cite journal  | last1 = Bollen | first1 = TL. | last2 = van Santvoort | first2 = HC. | last3 = Besselink | first3 = MG. | last4 = van Es | first4 = WH. | last5 = Gooszen | first5 = HG. | last6 = van Leeuwen | first6 = MS. | title = Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. | journal = Semin Ultrasound CT MR | volume = 28 | issue = 5 | pages = 371-83 | month = Oct | year = 2007 | doi =  | PMID = 17970553 }}</ref><ref name="Morgan-2008">{{Cite journal  | last1 = Morgan | first1 = DE. | title = Imaging of acute pancreatitis and its complications. | journal = Clin Gastroenterol Hepatol | volume = 6 | issue = 10 | pages = 1077-85 | month = Oct | year = 2008 | doi = 10.1016/j.cgh.2008.07.012 | PMID = 18928934 }}</ref>
::* If the diagnosis is established by abdominal pain and elevated pancreatic enzyme, a CECT is not usually required on admission.
::* If the diagnosis is established by abdominal pain and elevated pancreatic enzyme, a CECT is not usually required on admission.
-->
-->
==Types==
* '''Interstitial Edematous Pancreatitis'''
:▸ Acute inflammation of the pancreatic parenchyma and peripancreatic tissues, but without recognizable tissue necrosis.
:: ''CECT criteria''
::▸ Pancreatic parenchyma enhancement by intravenous contrast agent. <BR>
::▸ No findings of peripancreatic necrosis.
* '''Necrotizing Pancreatitis'''
:▸ Inflammation associated with pancreatic parenchymal necrosis and/or peripancreatic necrosis.
:: ''CECT criteria''
::▸ Lack of pancreatic parenchymal enhancement by intravenous contrast agent. <BR>
::▸ Presence of findings of peripancreatic necrosis.
* '''Infected Pancreatic Necrosis''':
:▸ Should be considered in patients with necrotizing pancreatitis who deteriorate or fail to improve after 7–10 days of hospitalization.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen |first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. |last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
:▸ May be presumed by the presence of extraluminal gas on CECT or when fine-needle aspiration is positive for bacteria and/or fungi on Gram stain and culture.<ref name="Banks-1995">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Gerzof | first2 = SG. | last3 = Langevin | first3 = RE. | last4 = Silverman | first4 = SG. | last5 = Sica | first5 = GT. | last6 = Hughes | first6 = MD. | title = CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. | journal = Int J Pancreatol | volume = 18 | issue = 3 | pages = 265-70 | month = Dec | year = 1995 | doi = 10.1007/BF02784951 | PMID = 8708399 }}</ref>
:▸ Antibiotics able to penetrate pancreatic necrosis (such as [[carbapenem]]s, [[quinolone]]s, and [[metronidazole]]) may be useful in delaying or sometimes totally avoiding intervention.<ref name="Petrov-2010">{{Cite journal  | last1 = Petrov | first1 = MS. | last2 = Shanbhag | first2 = S. | last3 = Chakraborty | first3 = M. | last4 = Phillips | first4 = AR. | last5 = Windsor | first5 = JA. | title = Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. | journal = Gastroenterology | volume = 139 | issue = 3 | pages = 813-20 | month = Sep | year = 2010 | doi = 10.1053/j.gastro.2010.06.010 | PMID = 20540942 }}</ref><ref name="van Santvoort-2011">{{Cite journal  | last1 = van Santvoort | first1 = HC. | last2 = Bakker | first2 = OJ. | last3 = Bollen | first3 = TL. | last4 = Besselink | first4 = MG. | last5 = Ahmed Ali | first5 = U. | last6 = Schrijver | first6 = AM. | last7 = Boermeester | first7 = MA. | last8 = van Goor | first8 = H. | last9 = Dejong | first9 = CH. | title = A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. | journal = Gastroenterology | volume = 141 | issue = 4 | pages = 1254-63 | month = Oct | year = 2011 | doi = 10.1053/j.gastro.2011.06.073 | PMID = 21741922 }}</ref>
==Complications==
===Organ Failure===
* '''''Modified Marshall Scoring System'''''
{| {{table}}
|+ '''Modified Marshall Scoring System<sup>†</sup>'''
| align="left" width=200px style="background:#f0f0f0;"|'''Organ System'''
| align="left" width=150px style="background:#f0f0f0;"|'''0'''
| align="left" width=150px style="background:#f0f0f0;"|'''1'''
| align="left" width=150px style="background:#f0f0f0;"|'''2'''
| align="left" width=150px style="background:#f0f0f0;"|'''3'''
| align="left" width=150px style="background:#f0f0f0;"|'''4'''
|-
| valign="bottom" width=200px | '''Respiratory''' <BR> PaO2/FiO2
| valign="bottom" width=150px | >400
| valign="bottom" width=150px | 301-400
| valign="bottom" width=150px | 201-300
| valign="bottom" width=150px | 101-200
| valign="bottom" width=150px | ≤101
|-
| valign="bottom" width=200px | '''Renal<sup>‡</sup>''' <BR> Creatinine (μmol/l) <BR> Creatinine (mg/dl)
| valign="bottom" width=150px | ≤134 <BR> <1.4
| valign="bottom" width=150px | 134-169 <BR> 1.4-1.8
| valign="bottom" width=150px | 170-310 <BR> 1.9-3.6
| valign="bottom" width=150px | 311-439 <BR> 3.6-4.9
| valign="bottom" width=150px | >439 <BR> >4.9
|-
| valign="bottom" width=200px | '''Cardiovascular''' <BR> Systolic Blood Pressure (mmHg)
| valign="bottom" width=150px | >90
| valign="bottom" width=150px | <90, fluid responsive
| valign="bottom" width=150px | <90, not fluid responsive
| valign="bottom" width=150px | <90, pH <7.3
| valign="bottom" width=150px | <90, pH <7.2
|-
|}
<sup>†</sup> A score of 2 or more in any system defines the presence of organ failure. <BR>
<sup>‡</sup> A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.
▸ ''For non-ventilated patients, the FiO2 can be estimated from below:''
{| {{table}}
| align="center" style="background:#f0f0f0;"|'''Supplemental oxygen (l/min)'''
| align="center" style="background:#f0f0f0;"|'''FiO2 (%)'''
|-
| Room air||21
|-
| 2||25
|-
| 4||30
|-
| 6–8 ||40
|-
| 9–10||50
|}
* '''Transient organ failure''' = organ failure resolves within 48 h.
* '''Persistent organ failure''' = organ failure persists for >48 h.<ref name="Johnson-2004">{{Cite journal  | last1 = Johnson | first1 = CD. | last2 = Abu-Hilal | first2 = M. | title = Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. | journal = Gut | volume = 53 | issue = 9 | pages = 1340-4 | month = Sep | year = 2004 | doi = 10.1136/gut.2004.039883 | PMID = 15306596 }}</ref><ref name="Mofidi-2006">{{Cite journal  | last1 = Mofidi | first1 = R. | last2 = Duff | first2 = MD. | last3 = Wigmore | first3 = SJ. | last4 = Madhavan | first4 = KK. | last5 = Garden | first5 = OJ. | last6 = Parks | first6 = RW. | title = Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. | journal = Br J Surg | volume = 93 | issue = 6 | pages = 738-44 | month = Jun | year = 2006 | doi = 10.1002/bjs.5290 | PMID = 16671062 }}</ref><ref name="Lytras-2008">{{Cite journal  | last1 = Lytras | first1 = D. | last2 = Manes | first2 = K. | last3 = Triantopoulou | first3 = C. | last4 = Paraskeva | first4 = C. | last5 = Delis | first5 = S. | last6 = Avgerinos | first6 = C. | last7 = Dervenis | first7 = C. | title = Persistent early organ failure: defining the high-risk group of patients with severe acute pancreatitis? | journal = Pancreas | volume = 36 | issue = 3 | pages = 249-54 | month = Apr | year = 2008 | doi = 10.1097/MPA.0b013e31815acb2c | PMID = 18362837 }}</ref>
===Local Complications===
▸ Should be suspected when there is persistence/recurrence of abdominal pain, secondary increases in pancreatic enzyme, increasing organ dysfunction, or the development of signs of [[sepsis]].<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen| first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen |first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. |last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Acute Peripancreatic Fluid Collection (APFC)'''
:▸ Peripancreatic fluid associated with interstitial edematous pancreatitis with no associated peripancreatic necrosis. This term applies only to areas of peripancreatic fluid seen within the first 4 weeks after onset of interstitial edematous pancreatitis and without the features of a pseudocyst.
:: ''CECT criteria''
::▸ Occurs in the setting of interstitial edematous pancreatitis. <BR>
::▸ Homogeneous collection with fluid density. <BR>
::▸ Confined by normal peripancreatic fascial planes. <BR>
::▸ No definable wall encapsulating the collection. <BR>
::▸ Adjacent to pancreas (no intrapancreatic extension).
* '''Pancreatic Pseudocyst'''
:▸ An encapsulated collection of fluid with a well defined inflammatory wall usually outside the pancreas with minimal or no necrosis. This entity usually occurs more than 4 weeks after onset of interstitial edematous pancreatitis to mature.
:: ''CECT criteria''
::▸ Well circumscribed, usually round or oval. <BR>
::▸ Homogeneous fluid density. <BR>
::▸ No non-liquid component. <BR>
::▸ Well defined wall; that is, completely encapsulated. <BR>
::▸ Maturation usually requires >4 weeks after onset of acute pancreatitis; occurs after interstitial edematous pancreatitis.
* '''Acute necrotic collection (ANC)'''
:▸ A collection containing variable amounts of both fluid and necrosis associated with necrotizing pancreatitis; the necrosis can involve the pancreatic parenchyma and/or the peripancreatic tissues.
:: ''CECT criteria''
::▸ Occurs only in the setting of acute necrotising pancreatitis. <BR>
::▸ Heterogeneous and non-liquid density of varying degrees in different locations (some appear homogeneous early in their course). <BR>
::▸ No definable wall encapsulating the collection. <BR>
::▸ Location—intrapancreatic and/or extrapancreatic.
* '''Walled-off necrosis (WON)'''
:▸ A mature, encapsulated collection of pancreatic and/or peripancreatic necrosis that has developed a well defined inflammatory wall. WON usually occurs >4 weeks after onset of necrotising pancreatitis.
:: ''CECT criteria''
::▸ Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear homogeneous). <BR>
::▸ Well defined wall, that is, completely encapsulated. <BR>
::▸ Location—intrapancreatic and/or extrapancreatic. <BR>
::▸ Maturation usually requires 4 weeks after onset of acute necrotizing pancreatitis
===Systemic Complications===
▸ Defined as exacerbation of pre-existing co-morbidity, such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis.
==Grades of Severity==
The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
* '''Mild acute pancreatitis'''
: ▸ No organ failure
: ▸ No local or systemic complications
* '''Moderately severe acute pancreatitis'''
: ▸ Organ failure that resolves within 48 h (transient organ failure) and/or
: ▸ Local or systemic complications without persistent organ failure
* '''Severe acute pancreatitis'''
: ▸ Persistent organ failure (>48 h)
: – Single organ failure
: – Multiple organ failure


==Causes==
==Causes==
===Life Threatening Causes===
===Life Threatening Causes===
''Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.''
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Acute pancreatitis is a life-threatening condition, especially if it progresses to necrotizing pancreatitis, and should be treated as such irrespective of the cause.
 
Acute pancreatitis from any cause may be life-threatening especially if it progresses to necrotizing pancreatitis.


===Common Causes===
===Common Causes===
Line 157: Line 34:
* [[Hypertriglyceridemia]] 1-4% cases <ref name="Fortson-1995">{{Cite journal  | last1 = Fortson | first1 = MR. | last2 = Freedman | first2 = SN. | last3 = Webster | first3 = PD. | title = Clinical assessment of hyperlipidemic pancreatitis. | journal = Am J Gastroenterol | volume = 90 | issue = 12 | pages = 2134-9 | month = Dec | year = 1995 | doi =  | PMID = 8540502 }}</ref>
* [[Hypertriglyceridemia]] 1-4% cases <ref name="Fortson-1995">{{Cite journal  | last1 = Fortson | first1 = MR. | last2 = Freedman | first2 = SN. | last3 = Webster | first3 = PD. | title = Clinical assessment of hyperlipidemic pancreatitis. | journal = Am J Gastroenterol | volume = 90 | issue = 12 | pages = 2134-9 | month = Dec | year = 1995 | doi =  | PMID = 8540502 }}</ref>


* Medication such as [[5-mercaptopurine]], [[azathioprine]], [[5-DDI]]<ref name="Yi-2012">{{Cite journal  | last1 = Yi | first1 = GC. | last2 = Yoon | first2 = KH. | last3 = Hwang | first3 = JB. | title = Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease. | journal = Pediatr Gastroenterol Hepatol Nutr | volume = 15 | issue = 4 | pages = 272-5 | month = Dec | year = 2012 | doi = 10.5223/pghn.2012.15.4.272 | PMID = 24010098 }}</ref>
* Medication such as [[mercaptopurine|5-mercaptopurine]], [[azathioprine]], [[5-DDI]]<ref name="Yi-2012">{{Cite journal  | last1 = Yi | first1 = GC. | last2 = Yoon | first2 = KH. | last3 = Hwang | first3 = JB. | title = Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease. | journal = Pediatr Gastroenterol Hepatol Nutr | volume = 15 | issue = 4 | pages = 272-5 | month = Dec | year = 2012 | doi = 10.5223/pghn.2012.15.4.272 | PMID = 24010098 }}</ref>


* [[Pancreatic tumor]]<ref name="Köhler-1987">{{Cite journal  | last1 = Köhler | first1 = H. | last2 = Lankisch | first2 = PG. | title = Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma. | journal = Pancreas | volume = 2 | issue = 1 | pages = 117-9 | month =  | year = 1987 | doi =  | PMID = 2437571 }}</ref>
* [[Pancreatic tumor]]<ref name="Köhler-1987">{{Cite journal  | last1 = Köhler | first1 = H. | last2 = Lankisch | first2 = PG. | title = Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma. | journal = Pancreas | volume = 2 | issue = 1 | pages = 117-9 | month =  | year = 1987 | doi =  | PMID = 2437571 }}</ref>


* Post - [[ERCP]]
* [[ERCP|Post-ERCP]]


==Management==
==Management==
Line 167: Line 44:


{{familytree/start |summary=Acute Pancreatitis}}
{{familytree/start |summary=Acute Pancreatitis}}
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms:''' <br> ❑ Severe abdominal pain and/or <br> ❑ Breathing difficulty and/or <br> ❑ Nausea & vomiting and/or <br> ❑ Hiccups sometimes </div> }}
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms:''' <br> ❑ Severe abdominal pain <br> ❑ Breathing difficulty <br> ❑ Nausea & vomiting <br> ❑ Hiccups sometimes </div> }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | A11 | | | | | | | | | | | | | | |A11=<div style="float: left; text-align: left; line-height: 150% ">'''Examine the patient:''' <br> ❑ Fever and/or <br> ❑ Hypotension and/or <br> ❑ [[Cullen's sign]] and/or <br> ❑ [[Grey-Turner's sign]] and/or <br> ❑  Tachypnea and/or <br> ❑ Abdominal distension and/or tenderness</div>}}
{{familytree | | | | | | | | | | | | | A11 | | | | | | | | | | | | | | |A11=<div style="float: left; text-align: left; line-height: 150% ">'''Examine the patient:''' <br> ❑ Fever<br> ❑ Hypotension <br> ❑ [[Cullen's sign]]<br> ❑ [[Grey-Turner's sign]]<br> ❑  Tachypnea<br> ❑ Abdominal distension and/or tenderness</div>}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | A12 | | | | | | | | | | | | | | |A12=<div style="float: left; text-align: left; line-height: 150% ">'''Consider alternative diagnosis:''' <br> ❑ [[Gallstones]] <br> ❑ [[Dissecting aortic aneurysm]] <br> ❑ [[Pancreatic pseudocyst]] </div> }}
{{familytree | | | | | | | | | | | | | A12 | | | | | | | | | | | | | | |A12=<div style="float: left; text-align: left; line-height: 150% ">'''Consider alternative diagnosis:''' <br> ❑ [[Gallstones]] <br> ❑ [[Dissecting aortic aneurysm]] <br> ❑ [[Pancreatic pseudocyst]] </div> }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | E01 |-|-|-|-|-|-|.| | |E01=Hemodynamic stability? }}
{{familytree | | | | | | | | | | | | | E01 |-|-|-|-|-|-|.| | |E01=❑ Assess hemodynamic stability }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | |!| |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | |!| |}}
{{familytree | | | | | | | | | | | | | Z01 | | | | | | Z02 | | | | |Z01 = Stable|Z02= Unstable|border=0 }}  
{{familytree | | | | | | | | | | | | | Z01 | | | | | | Z02 | | | | |Z01 = Stable|Z02= Unstable|border=0 }}  
Line 185: Line 62:
{{familytree | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria: Any 2 out of 3''' <br> ❑  Abdominal pain consistent with disease<br> ❑ Serum amylase or lipase values > 3 times normal <br> ❑ Consistent findings from abdominal imaging </div>}}
{{familytree | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria: Any 2 out of 3''' <br> ❑  Abdominal pain consistent with disease<br> ❑ Serum amylase or lipase values > 3 times normal <br> ❑ Consistent findings from abdominal imaging </div>}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | |D01=Acute Pancreatitis}}
{{familytree | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | |D01='''Acute Pancreatitis'''}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | F01 |-|-|-|-|-| F02 |-|.| | | | |F01=[[Systemic inflammatory response syndrome]]? '''(Urgent)''' |F02=Yes|"border=0" }}
{{familytree | | | | | | | | | | | | | F01 |-|-|-|-|-| F02 |-|.| | | | |F01=[[Systemic inflammatory response syndrome]]? '''(Urgent)''' |F02=Yes|"border=0" }}
Line 191: Line 68:
{{familytree |border=0 | | | | | | | | | | | | | AA1 | | | | | | | | | |!| | | | |AA1=No}}
{{familytree |border=0 | | | | | | | | | | | | | AA1 | | | | | | | | | |!| | | | |AA1=No}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | |!| | | | |}}
{{familytree | | | | | | | | | | | | | G01 | | | | | | | | | |!| | | | |G01=Risk stratification (Marshall scoring)'''(Urgent)'''}}
{{familytree | | | | | | | | | | | | | G01 | | | | | | | | | |!| | | | |G01=Risk stratification for organ failure<br> ([[Gallstone pancreatitis resident survival guide#Modified Marshall Scoring System|Marshall scoring]]) '''(Urgent)'''}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | |!| | | | |}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | |!| | | | |}}
{{familytree | | | | | | H01 | | | | | | | | | | | | H02 | | |!| | | | |H01=Lower risk |H02=Higher risk}}
{{familytree | | | | | | H01 | | | | | | | | | | | | H02 | | |!| | | | |H01=Lower risk |H02=Higher risk}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | |!| | | | |}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | |!| | | | |}}
{{familytree | | | | | | I01 | | | | | | | | | | | | I02 |-|-|'| | | | |I01=Admit to medical ward |I02=Admit to ICU '''(Urgent)'''}}
{{familytree | | | | | | I01 | | | | | | | | | | | | I02 |-|-|'| | | | |I01=Admit to medical ward |I02=Admit to ICU '''(Urgent)'''}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | J01 | | | | | | | | | | | | J02 | | | | | | | |J01=<div style="float: left; text-align: left; line-height: 150% "> '''Fluids: (Urgent)''' <br><br> ❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs <br> ❑ Reassess within 6 hrs after admission and for next 24-48 hrs
{{familytree | | | | | | J01 | | | | | | | | | | | | J02 | | | | | | | |J01=<div style="float: left; text-align: left; line-height: 150% "> '''Fluids: (Urgent)''' <br><br> ❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs <br> ❑ Reassess within 6 hrs after admission and for next 24-48 hrs
Line 208: Line 85:
'''Nutrition: (Urgent)'''  <br> ❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside <br> ❑ Consider enteral feeding if above not tolerated </div>}}
'''Nutrition: (Urgent)'''  <br> ❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside <br> ❑ Consider enteral feeding if above not tolerated </div>}}
{{familytree | | | | | | |`|-|-|-|-|-|-|v|-|-|-|-|-|-|'| | | | | | | | |}}
{{familytree | | | | | | |`|-|-|-|-|-|-|v|-|-|-|-|-|-|'| | | | | | | | |}}
{{familytree | | | | | | | | | | | | | K01 |-|-|-|-|-| K02 |-|-|-|-| K03 |K01=Cholangitis or biliary obstruction |K02=Yes |K03=ERCP within 24 hrs/Cholecystectomy to prevent recurrence }}
{{familytree | | | | | | | | | | | | | K01 |-|-|-|-|-| K02 |-|-|-|-| K03 |K01='''Cholangitis or biliary obstruction''' |K02=Yes |K03=ERCP within 24 hrs/Cholecystectomy to prevent recurrence<br> Click '''[[gallstone pancreatitis resident survival guide|here]]''' for more details}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AK1 | | | | | | | | |AK1=No | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AK1 | | | | | | | | |AK1=No | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | L01 | | | | | | | | | | | | | | |L01=Consider MRCP/EUS}}
{{familytree | | | | | | | | | | | | | L01 | | | | | | | | | | | | | | |L01=Consider MRCP/EUS}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | M01 |-|-|-|-|-| M02 |-|-|-|-| M03 | | | | | |M01=Clinical improvement within 48-72 hrs |M02=Yes |M03=Assess for ability to maintain oral feeding at the end of 1 week}}
{{familytree | | | | | | | | | | | | | M01 |-|-|-|-|-| M02 |-|-|-|-| M03 | | | | | |M01=Clinical improvement within 48-72 hrs |M02=Yes |M03=Assess for ability to maintain oral feeding at the end of 1 week}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | }}
{{familytree |border=0 | | | | | | | | | | | | | AE1 | | | |AE1=N o  | | | | | | | | | | |!|}}
{{familytree |border=0 | | | | | | | | | | | | | AE1 | | | |AE1=N o  | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | |!|}}
{{familytree | | | | | | | | | | | | | N01 | | | | | | | | | | | | | N02 | | | | |N01=CECT/MRI |N02=Recovery}}
{{familytree | | | | | | | | | | | | | N01 | | | | | | | | | | | | | N02 | | | | |N01=CECT/MRI |N02=Recovery}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | O01 | | | | | | | | | | | | | | |O01=Pancreatic necrosis}}
{{familytree | | | | | | | | | | | | | O01 | | | | | | | | | | | | | | |O01='''Pancreatic necrosis'''}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | P01 |-|-|-|-|-| P02 |-|-|-|-| P03 |P01=Failure to improve clinically after 7-10 days of hospitalization|P02=Yes|P03=Supportive treatment|}}
{{familytree | | | | | | | | | | | | | P01 |-|-|-|-|-| P02 |-|-|-|-| P03 |P01=Failure to improve clinically after 7-10 days of hospitalization|P02=Yes|P03=Supportive treatment|}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | || | AF1 | | | | |AF1=No | | | | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | AF1 | | | | |AF1=No | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | Q01 | | | | | | | | | | | | | | |Q01=Suspect Infected necrosis}}
{{familytree | | | | | | | | | | | | | Q01 | | | | | | | | | | | | | | |Q01=Suspected infected necrosis}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | R01 |-|-|-|-| R02 |-|-|-|-| R03 |R01=<div style="float: left; text-align: left; line-height: 150% "> <br> ❑ CT guided FNA  
{{familytree | | | | | | | | | | | | | R01 |-|-|-|-| R02 |-|-|-|-| R03 |R01=<div style="float: left; text-align: left; line-height: 150% "> <br> ❑ CT guided FNA  
Line 236: Line 113:
{{familytree |border=0 | | | | | | | | | | | | | |  AG1  | | | | | | |AG1=Gram stain & Culture(+) | | | | | | |}}
{{familytree |border=0 | | | | | | | | | | | | | |  AG1  | | | | | | |AG1=Gram stain & Culture(+) | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | S01 | | | | | | | | | | | | | | |S01=Infected necrosis}}
{{familytree | | | | | | | | | | | | | S01 | | | | | | | | | | | | | | |S01='''Infected necrosis'''}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | |}}
{{familytree | | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | |}}
{{familytree | | | | | | T01 | | | | | | | | | | | | T02 | | | | | | | |T01=Clinically stable|T02=Clinically unstable}}
{{familytree | | | | | | T01 | | | | | | | | | | | | T02 | | | | | | | |T01=Clinically stable|T02=Clinically unstable}}
Line 243: Line 120:
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree/end}}
{{familytree/end}}
<sup>†</sup>'''ALT:''' Alanine aminotransferase; '''AST:''' Aspartate aminotransferase; '''BUN:''' Blood urea nitrogen; '''CBC:''' Complete blood count; '''CECT:''' Contrast-enhanced computed tomography; '''CT:''' Computed tomography; '''ERCP:''' Endoscopic retrograde cholangiopancreatography; '''EU:''' Endoscopic ultrasound; '''FNA:''' Fine-needle aspiration; '''GGT:''' Gamma-glutamyl transpeptidase; '''ICU''': Intensive care unit; '''IV:''' Intravenous; '''MRCP:''' Magnetic resonance cholangiopancreatography; '''MRI:''' Magnetic resonance imaging; '''Q8h:''' Every 8 hours; '''Q12h:''' Every 12 hours
 
<span style="font-size:85%">'''ALT:''' Alanine aminotransferase; '''AST:''' Aspartate aminotransferase; '''BUN:''' Blood urea nitrogen; '''CBC:''' Complete blood count; '''CECT:''' Contrast-enhanced computed tomography; '''CT:''' Computed tomography; '''ERCP:''' Endoscopic retrograde cholangiopancreatography; '''EU:''' Endoscopic ultrasound; '''FNA:''' Fine-needle aspiration; '''GGT:''' Gamma-glutamyl transpeptidase; '''ICU''': Intensive care unit; '''IV:''' Intravenous; '''MRCP:''' Magnetic resonance cholangiopancreatography; '''MRI:''' Magnetic resonance imaging; '''Q8h:''' Every 8 hours; '''Q12h:''' Every 12 hours </span>
 
==Modified Marshall Scoring System==
{| {{table}}
|+ '''Modified Marshall Scoring System<sup>†</sup>'''
| align="left" width=200px style="background:#f0f0f0;"|'''Organ System'''
| align="left" width=150px style="background:#f0f0f0;"|'''0'''
| align="left" width=150px style="background:#f0f0f0;"|'''1'''
| align="left" width=150px style="background:#f0f0f0;"|'''2'''
| align="left" width=150px style="background:#f0f0f0;"|'''3'''
| align="left" width=150px style="background:#f0f0f0;"|'''4'''
|-
| valign="bottom" width=200px | '''Respiratory''' <BR> PaO2/FiO2
| valign="bottom" width=150px | >400
| valign="bottom" width=150px | 301-400
| valign="bottom" width=150px | 201-300
| valign="bottom" width=150px | 101-200
| valign="bottom" width=150px | ≤101
|-
| valign="bottom" width=200px | '''Renal<sup>‡</sup>''' <BR> Creatinine (μmol/l) <BR> Creatinine (mg/dl)
| valign="bottom" width=150px | ≤134 <BR> <1.4
| valign="bottom" width=150px | 134-169 <BR> 1.4-1.8
| valign="bottom" width=150px | 170-310 <BR> 1.9-3.6
| valign="bottom" width=150px | 311-439 <BR> 3.6-4.9
| valign="bottom" width=150px | >439 <BR> >4.9
|-
| valign="bottom" width=200px | '''Cardiovascular''' <BR> Systolic Blood Pressure (mmHg)
| valign="bottom" width=150px | >90
| valign="bottom" width=150px | <90, fluid responsive
| valign="bottom" width=150px | <90, not fluid responsive
| valign="bottom" width=150px | <90, pH <7.3
| valign="bottom" width=150px | <90, pH <7.2
|-
|}
<sup>†</sup> A score of 2 or more in any system defines the presence of organ failure. <BR>
<sup>‡</sup> A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.
 
▸ ''For non-ventilated patients, the FiO2 can be estimated from below:''
{| {{table}}
| align="center" style="background:#f0f0f0;"|'''Supplemental oxygen (l/min)'''
| align="center" style="background:#f0f0f0;"|'''FiO2 (%)'''
|-
| Room air||21
|-
| 2||25
|-
| 4||30
|-
| 6–8 ||40
|-
| 9–10||50
|}
 
==Grades of Severity==
The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.<ref name="Banks-2013">{{Cite journal  | last1 = Banks | first1 = PA. | last2 = Bollen | first2 = TL. | last3 = Dervenis | first3 = C. | last4 = Gooszen | first4 = HG. | last5 = Johnson | first5 = CD. | last6 = Sarr | first6 = MG. | last7 = Tsiotos | first7 = GG. | last8 = Vege | first8 = SS. | last9 = Acosta | first9 = JM. | title = Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. | journal = Gut | volume = 62 | issue = 1 | pages = 102-11 | month = Jan | year = 2013 | doi = 10.1136/gutjnl-2012-302779 | PMID = 23100216 }}</ref>
 
* '''Mild acute pancreatitis'''
: ▸ No organ failure
: ▸ No local or systemic complications
* '''Moderately severe acute pancreatitis'''
: ▸ Organ failure that resolves within 48 h (transient organ failure) and/or
: ▸ Local or systemic complications without persistent organ failure
* '''Severe acute pancreatitis'''
: ▸ Persistent organ failure (>48 h)
: – Single organ failure
: – Multiple organ failure


==Do's==
==Do's==

Latest revision as of 00:13, 13 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]

Overview

Acute pancreatitis is the acute inflammation of the pancreas.

Diagnostic Criteria

▸ Diagnosis is established by the presence of two of the three following criteria (strong recommendation, moderate quality of evidence):[1]

  • Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back)
  • Serum lipase or amylase ≥ 3 x ULN
  • Characteristic findings on contrast-enhanced computed tomography (CECT), MRI, or transabdominal US

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Acute pancreatitis is a life-threatening condition, especially if it progresses to necrotizing pancreatitis, and should be treated as such irrespective of the cause.

Common Causes

Management

Shown below is a diagram depicting the management of acute pancreatitis according to the American College of Gastroenterology (ACG).[7]

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Severe abdominal pain
❑ Breathing difficulty
❑ Nausea & vomiting
❑ Hiccups sometimes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Fever
❑ Hypotension
Cullen's sign
Grey-Turner's sign
❑ Tachypnea
❑ Abdominal distension and/or tenderness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
Gallstones
Dissecting aortic aneurysm
Pancreatic pseudocyst
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess hemodynamic stability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable
 
 
 
 
 
Unstable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order Labs: (Urgent)
CBC
Hematocrit
BUN
Creatinine
Amylase
Lipase
Triglyceride
❑ Total bilirubin
❑ Direct bilirubin
Albumin
AST
ALT
Alkaline phosphatase
GGT
Chest X-ray
Order imaging studies: (Urgent)
Trans abdominal USG (TAUSG)
 
 
 
 
 
Stabilize the patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic criteria: Any 2 out of 3
❑ Abdominal pain consistent with disease
❑ Serum amylase or lipase values > 3 times normal
❑ Consistent findings from abdominal imaging
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute Pancreatitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemic inflammatory response syndrome? (Urgent)
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk stratification for organ failure
(Marshall scoring) (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lower risk
 
 
 
 
 
 
 
 
 
 
 
Higher risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Admit to medical ward
 
 
 
 
 
 
 
 
 
 
 
❑ Admit to ICU (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluids: (Urgent)

❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs
❑ Reassess within 6 hrs after admission and for next 24-48 hrs

Analgesics: (Urgent)

❑ Opioids are preferred
❑ Mepridine & morphine may be used as IV drips/pt. controlled analgesia


Nutrition: (Urgent)

❑ Immediate oral feeding as soon as pain, vomiting, nausea subside
 
 
 
 
 
 
 
 
 
 
 
Fluids: (Urgent)
❑ Initiate with a fluid bolus
❑ Aggressive hydration at 250-500 ml/hr with Ringer's lactate in first 12-24 hrs
❑ Reassess within 6 hrs after admission and for next 24-48 hrs

Analgesics: (Urgent)
❑ Opioids are preferred
❑ Mepridine & morphine may be used as IV drips/pt. controlled analgesia


Nutrition: (Urgent)
❑ Nasogastric or nasojejunal feeding may be initiated once pain, vomiting, nausea subside
❑ Consider enteral feeding if above not tolerated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cholangitis or biliary obstruction
 
 
 
 
 
Yes
 
 
 
 
❑ ERCP within 24 hrs/Cholecystectomy to prevent recurrence
Click here for more details
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Consider MRCP/EUS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical improvement within 48-72 hrs
 
 
 
 
 
Yes
 
 
 
 
❑ Assess for ability to maintain oral feeding at the end of 1 week
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ CECT/MRI
 
 
 
 
 
 
 
 
 
 
 
 
Recovery
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pancreatic necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Failure to improve clinically after 7-10 days of hospitalization
 
 
 
 
 
Yes
 
 
 
 
❑ Supportive treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspected infected necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ CT guided FNA

❑ Empiric antibiotics, necrosis penetrating:

❑ Meropenem 1g IV Q8h
❑ Ciprofloxacin 400mg IV Q12h plus metronidazole 500 mg IV Q8h for 14 days
 
 
 
 
Gram stain & Culture (-)
 
 
 
 
❑ Supportive treatment
❑ Consider repeat CT FNA every 7 days if no improvement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gram stain & Culture(+)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infected necrosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinically stable
 
 
 
 
 
 
 
 
 
 
 
Clinically unstable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Continue antibiotics & observe
❑ If asymptomatic no debridement, else consider surgical consultation
 
 
 
 
 
 
 
 
 
 
 
Prompt surgical consultation (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CBC: Complete blood count; CECT: Contrast-enhanced computed tomography; CT: Computed tomography; ERCP: Endoscopic retrograde cholangiopancreatography; EU: Endoscopic ultrasound; FNA: Fine-needle aspiration; GGT: Gamma-glutamyl transpeptidase; ICU: Intensive care unit; IV: Intravenous; MRCP: Magnetic resonance cholangiopancreatography; MRI: Magnetic resonance imaging; Q8h: Every 8 hours; Q12h: Every 12 hours

Modified Marshall Scoring System

Modified Marshall Scoring System
Organ System 0 1 2 3 4
Respiratory
PaO2/FiO2
>400 301-400 201-300 101-200 ≤101
Renal
Creatinine (μmol/l)
Creatinine (mg/dl)
≤134
<1.4
134-169
1.4-1.8
170-310
1.9-3.6
311-439
3.6-4.9
>439
>4.9
Cardiovascular
Systolic Blood Pressure (mmHg)
>90 <90, fluid responsive <90, not fluid responsive <90, pH <7.3 <90, pH <7.2

A score of 2 or more in any system defines the presence of organ failure.
A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline creatinine ≥134 μmol/l or ≥1.4 mg/dl.

For non-ventilated patients, the FiO2 can be estimated from below:

Supplemental oxygen (l/min) FiO2 (%)
Room air 21
2 25
4 30
6–8 40
9–10 50

Grades of Severity

The definitions of severity in acute pancreatitis according to the revised Atlanta classification is as follows.[1]

  • Mild acute pancreatitis
▸ No organ failure
▸ No local or systemic complications
  • Moderately severe acute pancreatitis
▸ Organ failure that resolves within 48 h (transient organ failure) and/or
▸ Local or systemic complications without persistent organ failure
  • Severe acute pancreatitis
▸ Persistent organ failure (>48 h)
– Single organ failure
– Multiple organ failure

Do's

  • Patients who fail to improve clinically (e.g., persistent abdominal pain, fever, nausea, unable to begin oral intake) within the first 48-72 h after admission.
  • Patients in whom the diagnosis is unclear.

Dont's

References

  1. 1.0 1.1 Banks, PA.; Bollen, TL.; Dervenis, C.; Gooszen, HG.; Johnson, CD.; Sarr, MG.; Tsiotos, GG.; Vege, SS.; Acosta, JM. (2013). "Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus". Gut. 62 (1): 102–11. doi:10.1136/gutjnl-2012-302779. PMID 23100216. Unknown parameter |month= ignored (help)
  2. Yang, AL.; Vadhavkar, S.; Singh, G.; Omary, MB. (2008). "Epidemiology of alcohol-related liver and pancreatic disease in the United States". Arch Intern Med. 168 (6): 649–56. doi:10.1001/archinte.168.6.649. PMID 18362258. Unknown parameter |month= ignored (help)
  3. Forsmark, CE.; Baillie, J. (2007). "AGA Institute technical review on acute pancreatitis". Gastroenterology. 132 (5): 2022–44. doi:10.1053/j.gastro.2007.03.065. PMID 17484894. Unknown parameter |month= ignored (help)
  4. Fortson, MR.; Freedman, SN.; Webster, PD. (1995). "Clinical assessment of hyperlipidemic pancreatitis". Am J Gastroenterol. 90 (12): 2134–9. PMID 8540502. Unknown parameter |month= ignored (help)
  5. Yi, GC.; Yoon, KH.; Hwang, JB. (2012). "Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease". Pediatr Gastroenterol Hepatol Nutr. 15 (4): 272–5. doi:10.5223/pghn.2012.15.4.272. PMID 24010098. Unknown parameter |month= ignored (help)
  6. Köhler, H.; Lankisch, PG. (1987). "Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma". Pancreas. 2 (1): 117–9. PMID 2437571.
  7. Tenner, S.; Baillie, J.; DeWitt, J.; Vege, SS. (2013). "American College of Gastroenterology guideline: management of acute pancreatitis". Am J Gastroenterol. 108 (9): 1400–15, 1416. doi:10.1038/ajg.2013.218. PMID 23896955. Unknown parameter |month= ignored (help)
  8. Arvanitakis, M.; Delhaye, M.; De Maertelaere, V.; Bali, M.; Winant, C.; Coppens, E.; Jeanmart, J.; Zalcman, M.; Van Gansbeke, D. (2004). "Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis". Gastroenterology. 126 (3): 715–23. PMID 14988825. Unknown parameter |month= ignored (help)
  9. Zaheer, A.; Singh, VK.; Qureshi, RO.; Fishman, EK. (2013). "The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines". Abdom Imaging. 38 (1): 125–36. doi:10.1007/s00261-012-9908-0. PMID 22584543. Unknown parameter |month= ignored (help)
  10. Bollen, TL.; Singh, VK.; Maurer, R.; Repas, K.; van Es, HW.; Banks, PA.; Mortele, KJ. (2011). "Comparative evaluation of the modified CT severity index and CT severity index in assessing severity of acute pancreatitis". AJR Am J Roentgenol. 197 (2): 386–92. doi:10.2214/AJR.09.4025. PMID 21785084. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources